Balta Elizabeth 4

4 · Jade Biosciences, Inc. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 14, 2026

Jade Biosciences (JBIO) CLO Elizabeth Balta Receives RSUs & Option Grant

What Happened

Elizabeth Balta, Chief Legal Officer and Corporate Secretary of Jade Biosciences (JBIO), received equity awards reported on 2026-02-12: 28,125 restricted stock units (RSUs) and a derivative award covering 168,750 shares (an option/award). Both awards were reported as acquired at $0.00 (no cash outlay reported).

Key Details

Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (timely).
Awards: 28,125 RSUs (each converts to one share upon vesting) and a derivative option for 168,750 shares.
Vesting (per footnotes): RSUs vest 25% on each of the first four anniversaries of 02/15/2026 (subject to continued service). The option vests 25% on 02/15/2027, then the remaining 75% vests in equal monthly installments over the next three years (subject to continued service).
Price/value: Reported at $0.00 per share on the Form 4 (grant/award, not an open-market purchase or sale).
Shares owned after transaction: Not specified in the information provided.
Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding sale, or late filing indicated.

Context

These are compensation awards (not sales or open-market purchases). RSUs are a contingent right to receive shares when they vest; the derivative award is a right to purchase shares that vests over time. Such grants are common for executive compensation and reflect future vesting rather than an immediate change in market ownership.

Form 4

Period: 2026-02-12

See Remarks

Transactions

Award
Common Stock
[F1]
2026-02-12+28,125→ 28,125 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-12+168,750→ 168,750 total
Exercise: $14.81Exp: 2036-02-11→ Common Stock (168,750 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
[F2]This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Signature

/s/ Elizabeth Balta|2026-02-13

1 file